WINNIPEG, Manitoba - (January 15, 2004) Medicure
Inc. (TSX:MPH), a cardiovascular drug discovery and development
company, is pleased to announce that it will be presenting at two
major international biotech conferences in January and February.
On January 20, 2004, Medicure will be making a corporate presentation
at BioData 2004 in Geneva, Switzerland, and on February 24, 2004,
it will present at the BIO CEO & Investor Conference in New
York City.
BioData 2004 will bring together decision-makers and executives
from the European and North American biotechnology, pharmaceutical
and high tech industries, along with fund managers, analysts following
the life sciences sector. More than 700 delegates are expected to
attend the conference, which will feature 60 internationally distinguished
speakers and 90 corporate presentations from biotech companies from
around the world. Medicure's presentation will be 25 minutes in
duration, including a question and answer session.
Now in its sixth year, the BIO CEO & Investor Conference has
emerged as one the industry's leading investor conferences. Hosted
by the Biotechnology Industry Organization (BIO) - the world's largest
biotech industry organization - the conference will bring together
key industry players to examine investment opportunities and issues
affecting the biotechnology industry. Participants will include
senior biotech executives, institutional and venture capital investors,
industry analysts, corporate finance executives and experts from
the scientific and medical communities. Medicure is one of only
50 companies that were selected to partake in the poster presentations
at the event's International Reception and Networking Exhibition,
which is expected to attract more than 1,000 people.
"We are pleased to have been given the opportunity to present
the Medicure story to audiences at such prestigious events,"
said Albert D. Friesen, Ph.D., Medicure Chairman, President and
CEO. "We have a very exciting and positive story to tell and
our participation on the world stage at conferences of this stature
reflects the growing recognition of Medicure internationally. Presenting
at such a highly recognized investor conferences allows us to broaden
the Medicure's exposure and enhance our visibility in the U.S. and
European markets."
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
